After 3 initial monthly injections, current dosing intervals range from every 8 to 16 weeks in patients with wAMD and DME and every 8 to 12 weeks in patients with DR.

Enhertu (fam-trastuzumab deruxtecan-nxki) is currently indicated as a second-line therapy for HER2-positive metastatic breast cancer.

Overall, 2679 pregnancy-related deaths could have been prevented if the national rate was reduced to the lowest state rate.

HealthDay News — A senior government health researcher has announced his retirement, accusing the National Institutes of Health (NIH) of censoring his latest findings on ultra-processed food. Kevin ...

Poor communication contributed to 24% of safety incidents in 42 studies that examined its contribution along with other causes.

“Midafternoon dosing of inhaled beclomethasone dipropionate better improved nocturnal lung function and inflammatory biomarkers compared with the alternative dosage timings without additional adrenal ...

Seven recommendations developed, including use of floating immunoreactive trypsinogen cutoff over fixed cutoff.

Treatment options are limited for those with sudden liver failure and the condition has a death rate as high as 50%.

Penmenvy combines the antigenic components of Bexsero (meningococcal Group B vaccine) and Menveo (meningococcal Groups A, C, Y, and W-135 oligosaccharide diphtheria CRM197 conjugate vaccine).

Pfizer's Abrysvo and GSK's Arexvy both received FDA-approval b in 2024 to include immunization of adults aged 50 to 59 years at increased risk for RSV disease.

The updated recommendations are pending final approval by the director of the CDC and the Department of Health and Human Services.

The CSU indication is the seventh disease driven in part by underlying type 2 inflammation in which Dupixent has received approval.